{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:48:31Z","timestamp":1777535311198,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T00:00:00Z","timestamp":1502323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jfma.2018.02.001","type":"journal-article","created":{"date-parts":[[2018,3,9]],"date-time":"2018-03-09T09:13:35Z","timestamp":1520586815000},"page":"134-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"P1","title":["Janus kinase-1 and 3 in ankylosing spondylitis"],"prefix":"10.1016","volume":"118","author":[{"given":"Hsien-Tzung","family":"Liao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzu-Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Hsiung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-An","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Chih","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung-Tei","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4154-4018","authenticated-orcid":false,"given":"Chang-Youh","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2018.02.001_bib1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0889-857X(21)00888-7","article-title":"Ankylosing spondylitis and other spondyloarthropathies","volume":"16","author":"Khan","year":"1990","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jfma.2018.02.001_bib2","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1093\/rheumatology\/kei047","article-title":"The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis","volume":"44","author":"Zochling","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jfma.2018.02.001_bib3","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 Update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jfma.2018.02.001_bib4","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/art.39298","article-title":"American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"68","author":"Ward","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jfma.2018.02.001_bib5","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3899\/jrheum.141001","article-title":"2014 Update of the Canadian Rheumatology Association\/Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis. Part II: specific management recommendations","volume":"42","author":"Rohekar","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jfma.2018.02.001_bib6","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/rheumatology\/33.10.927","article-title":"Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity","volume":"33","author":"Gratac\u00f3s","year":"1994","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.jfma.2018.02.001_bib7","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/art.37936","article-title":"Combinatorial control of Th17 and Th1 cell functions by genetic variations in genes associated with the interleukin-23 signaling pathway in spondyloarthritis","volume":"65","author":"Coffre","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jfma.2018.02.001_bib8","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1056\/NEJMra1406182","article-title":"Ankylosing spondylitis and axial spondyloarthritis","volume":"374","author":"Taurog","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2018.02.001_bib9","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nrrheum.2012.41","article-title":"Genetics of spondyloarthritis\u2013beyond the MHC","volume":"8","author":"Reveille","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jfma.2018.02.001_bib10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2174\/1568010053586372","article-title":"Inflammatory mediators as potential therapeutic targets in the spine","volume":"4","author":"Roberts","year":"2005","journal-title":"Curr Drug Targets Inflamm Allergy"},{"key":"10.1016\/j.jfma.2018.02.001_bib11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jbspin.2014.07.011","article-title":"Essential role for CD103+ cells in the pathogenesis of spondyloarthritides","volume":"82","author":"Berthelot","year":"2015","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jfma.2018.02.001_bib12","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nri2094","article-title":"Cytokines in the pathogenesis of rheumatoid arthritis","volume":"7","author":"McInnes","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jfma.2018.02.001_bib13","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.molimm.2006.11.025","article-title":"Cytokine receptor signaling through the JAK-STAT-SOCS pathway in disease","volume":"44","author":"O'Sullivan","year":"2007","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jfma.2018.02.001_bib14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00281-009-0189-9","article-title":"Th17 cytokines and arthritis","volume":"32","author":"Lubberts","year":"2010","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jfma.2018.02.001_bib15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jfma.2018.02.001_bib16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1600-065X.2008.00644.x","article-title":"Therapeutic targeting of Janus kinases","volume":"223","author":"Pesu","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jfma.2018.02.001_bib17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jfma.2018.02.001_bib18","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/nri1226","article-title":"Regulation of JAK-STAT signalling in the immune system","volume":"3","author":"Shuai","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jfma.2018.02.001_bib19","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.immuni.2008.03.002","article-title":"Cytokine signaling modules in inflammatory responses","volume":"28","author":"O'Shea","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.jfma.2018.02.001_bib20","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jfma.2018.02.001_bib21","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis. the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jfma.2018.02.001_bib22","first-page":"2281","article-title":"A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index","volume":"21","author":"Calin","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jfma.2018.02.001_bib23","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/rheumatology\/35.1.66","article-title":"The Bath Ankylosing Spondylitis Patient Global Score (BAS-G)","volume":"35","author":"Jones","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.jfma.2018.02.001_bib24","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.62.9.817","article-title":"International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis","volume":"62","author":"Braun","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jfma.2018.02.001_bib25","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP690,550)","volume":"7","author":"Ghoreschi","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.jfma.2018.02.001_bib26","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1136\/ard.2011.150284","article-title":"The JAK inhibitor CP690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon","volume":"71","author":"Rosengren","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jfma.2018.02.001_bib27","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/bjd.12049","article-title":"STAT1 expression and activation is increased in lesional psoriatic skin","volume":"168","author":"Hald","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jfma.2018.02.001_bib28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/annrheumdis-2014-207201","article-title":"Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors","volume":"75","author":"Gao","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jfma.2018.02.001_bib29","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.4049\/jimmunol.1101228","article-title":"Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2","volume":"187","author":"Lu","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.jfma.2018.02.001_bib30","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/cei.12377","article-title":"Dysregulation of the suppressor of cytokine signalling 3-signal transducer and activator of transcription-3 pathway in the aetiopathogenesis of Sj\u00f6gren's syndrome","volume":"177","author":"Vartoukian","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jfma.2018.02.001_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2013.06.007","article-title":"Involvement of JAK\/STAT signaling in the pathogenesis of inflammatory bowel disease","volume":"76","author":"Coskun","year":"2013","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jfma.2018.02.001_bib32","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1002\/art.34649","article-title":"JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production","volume":"64","author":"LaBranche","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jfma.2018.02.001_bib33","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/ar2642","article-title":"Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis","volume":"11","author":"Lories","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jfma.2018.02.001_bib34","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/1759720X12444175","article-title":"The role of bone morphogenetic proteins in ankylosing spondylitis","volume":"4","author":"Carter","year":"2012","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.jfma.2018.02.001_bib35","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1126\/science.150.3698.893","article-title":"Bone: formation by autoinduction","volume":"150","author":"Urist","year":"1965","journal-title":"Science"},{"key":"10.1016\/j.jfma.2018.02.001_bib36","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664617305843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664617305843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:38:50Z","timestamp":1760539130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664617305843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0929664617305843"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2018.02.001","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Janus kinase-1 and 3 in ankylosing spondylitis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2018.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}